- Home
- TLPH vs BOLT Comparison
TLPH vs BOLT Comparison
Compare TLPH & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLPH
- BOLT
- Stock Information
- Founded
- TLPH 2005
- BOLT 2015
- Country
- TLPH United States
- BOLT United States
- Employees
- TLPH N/A
- BOLT N/A
- Industry
- TLPH Biotechnology: Pharmaceutical Preparations
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- TLPH Health Care
- BOLT Health Care
- Exchange
- TLPH Nasdaq
- BOLT Nasdaq
- Market Cap
- TLPH 11.1M
- BOLT 11.5M
- IPO Year
- TLPH 2011
- BOLT 2021
- Fundamental
- Price
- TLPH $1.25
- BOLT $6.18
- Analyst Decision
- TLPH Strong Buy
- BOLT Buy
- Analyst Count
- TLPH 1
- BOLT 4
- Target Price
- TLPH $6.00
- BOLT $34.00
- AVG Volume (30 Days)
- TLPH 480.8K
- BOLT 37.6K
- Earning Date
- TLPH 11-12-2025
- BOLT 11-14-2025
- Dividend Yield
- TLPH N/A
- BOLT N/A
- EPS Growth
- TLPH N/A
- BOLT N/A
- EPS
- TLPH N/A
- BOLT N/A
- Revenue
- TLPH $27,000.00
- BOLT $4,167,000.00
- Revenue This Year
- TLPH N/A
- BOLT N/A
- Revenue Next Year
- TLPH $14,533.26
- BOLT N/A
- P/E Ratio
- TLPH N/A
- BOLT N/A
- Revenue Growth
- TLPH N/A
- BOLT N/A
- 52 Week Low
- TLPH $0.38
- BOLT $4.59
- 52 Week High
- TLPH $1.45
- BOLT $14.00
- Technical
- Relative Strength Index (RSI)
- TLPH 64.99
- BOLT 58.64
- Support Level
- TLPH $1.12
- BOLT $5.61
- Resistance Level
- TLPH $1.19
- BOLT $6.35
- Average True Range (ATR)
- TLPH 0.11
- BOLT 0.32
- MACD
- TLPH -0.01
- BOLT 0.02
- Stochastic Oscillator
- TLPH 59.83
- BOLT 69.32
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.